Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Marseille – page 99

1 478 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Marseille at a glance
1 478
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 478 trials in Marseille

Open in trial search

Neuroblastoma+4

Not recruiting

Study on Ribociclib, Topotecan, and Temozolomide for Children and Young Adults (12 months - 21 years) with Relapsed or Refractory Neuroblastoma and Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Ribociclib
  • Sponsor:Novartis Pharma AG

Hereditary angioedema

Not recruiting

Study on Long-Term Safety of Donidalorsen for Patients with Hereditary Angioedema

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Donidalorsen
  • Sponsor:Ionis Pharmaceuticals Inc.

Idiopathic pulmonary fibrosis

Not recruiting

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bi 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Dementia Alzheimer's type

Not recruiting

Study on the Effects of AR1001 (Mirodenafil Dihydrochloride) for Patients with Early Alzheimer's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Mirodenafil Dihydrochloride
  • Sponsor:Aribio Co. Ltd.

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study on Atezolizumab for Patients with Non-Small Cell Lung Cancer After Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Neoplasm malignant+1

Not recruiting

Study of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Squamous cell carcinoma of head and neck

Not recruiting

Study of Lenvatinib and Pembrolizumab for Patients with Recurrent or Metastatic Head and Neck Cancer After Platinum and Immunotherapy Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study on the Safety and Effectiveness of Vepdegestrant and PF-07220060 for Adults with ER+/HER2- Advanced or Metastatic Breast Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:(3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
  • Sponsor:Pfizer Inc.

Follicular lymphoma

Not recruiting

Study on Mosunetuzumab and Lenalidomide for Patients with Untreated Follicular Lymphoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:LYSARC

Cutaneous T-cell lymphoma+1

Not recruiting

Study of Lacutamab Alone or with Chemotherapy for Patients with Advanced T-Cell Lymphoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lacutamab
  • Sponsor:Innate Pharma

Metastatic malignant melanoma

Not recruiting

Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Io102 Hydrochloride
  • Sponsor:Io Biotech ApS

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

  • Advanced tumor treatments
  • Immunotherapy combinations
  • Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

  • Preventive cardiology
  • Emergency cardiac care
  • Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

  • Movement disorders
  • Autoimmune conditions
  • Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.